OBJECTIVE: @entity1037 , a potent 5-HT2a/2c, @entity935 D1D2D4 antagonist with anticholinergic activity, has a profile of known receptor affinity similar to that of @entity1088 . This pilot study examined the efficacy of @entity1037 for treatment-refractory childhood-onset @entity161 in eight @entity1 who had received 8-week open-label trials. For comparison, data are included from 15 @entity1 who had received 6-week open-label @entity1088 trials using identical rating instruments (largely by the same raters) in the same treatment setting. METHOD: Twenty-three @entity1 and adolescents with an onset of DSM-III-R @entity161 by age 12 for whom at least two different typical neuroleptics had been ineffective participated in the two separate studies. Some of the @entity1 were intolerant of @entity1088 , although it had been effective (n = 4). @entity1 receiving @entity1037 were evaluated over 8 weeks with the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms, the Scale for the Assessment of Negative Symptoms, and the Clinical Global Impressions Scale for Improvement. RESULTS: For the eight @entity1 who received @entity1037 trials, at week 8 there was a 17% improvement in the BPRS total score, a 27% improvement in the Scale for the Assessment of Negative Symptoms, and a 1% improvement in the Scale for the Assessment of Positive Symptoms, relative to "ideal" admission status on typical neuroleptics. In contrast, the magnitude of the effect sizes for each of the clinical ratings was larger at week 6 of the previous @entity1088 trial than for an 8-week @entity1037 trial, relative to admission status on typical neuroleptics. For the four @entity1 who had received both @entity1088 and @entity1037 , BPRS total scores were significantly lower at week 6 of @entity1088 treatment compared with week 6 of @entity1037 treatment (p = .03). CONCLUSION: These data provide preliminary evidence for the efficacy of @entity1037 for some @entity1 and adolescents with treatment-refractory @entity161 , but they also suggest the need for a more rigorous double-blind comparison of these two atypical antipsychotics.

Childhood-onset schizophrenia: an open-label study of XXXX in adolescents.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['Olanzapine', 'olanzapine']
@entity1037 :: (MESH:C076029,Chemical) :: ['olanzapine']
